Auxilium On a Roll ...
Health Care: Drugs
Acorda Therapeutics Inc. (ACOR: NASDAQ)
$22.07 0.23 | 1.05%
06/04/12 - 02:48 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 292.24M | 191.01M | 54.67M | 47.83M |
| Cost of Sales | 55.09M | 27.00M | 3.60M | 10.91M |
| Gross Operating Profit | 237.15M | 164.01M | 51.07M | 36.92M |
| Selling, General, and Administrative Expenses | 148.51M | 133.32M | 89.93M | 73.31M |
| Research & Development | 42.11M | 30.60M | 34.61M | 36.60M |
| Operating Income before D & A (EBITDA) | 46.53M | 89.66K | -73.47M | -72.99M |
| Depreciation & Amortization | 11.48M | 8.52M | 7.79M | 445.95K |
| Interest Income | 552.00K | 574.84K | 1.75M | 4.68M |
| Other Income - Net | -18.00K | 8.26K | -18.15K | 8.08K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 35.59M | -7.85M | -79.53M | -68.75M |
| Interest Expense | 3.57M | 3.92M | 4.41M | 5.59M |
| Pre-Tax Income | 32.02M | -11.77M | -83.94M | -74.34M |
| Income Taxes | 1.41M | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 30.60M | -11.77M | -83.94M | -74.34M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 30.60M | -11.77M | -83.94M | -74.34M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 30.60M | -11.77M | -83.94M | -74.34M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
30.60M | -11.77M | -83.94M | -74.34M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 30.60M | -11.77M | -83.94M | -74.34M |
| Basic EPS from Continuing Ops. | 0.78 | -0.31 | -2.22 | -2.19 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.78 | -0.31 | -2.22 | -2.19 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.78 | -0.31 | -2.22 | -2.19 |
| Basic Normalized Net Income/Share | 0.78 | -0.31 | -2.22 | -2.19 |
| EPS fr Continuing Ops. | 0.76 | -0.31 | -2.22 | -2.19 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.76 | -0.31 | -2.22 | -2.19 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.76 | -0.31 | -2.22 | -2.19 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.76 | -0.31 | -2.22 | -2.19 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ACOR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor13 Biotech Stocks Bought an...
- Contributor5 Biotech Drug-Launch Stock...
- Usergrandpicks
- UserPART 1 JPMorgan 28th Annual...
- ContributorBarron's Research Reports 3...
- UserUndervalued Biotech's
- UserPART 1 JPMorgan 27th Annual...
- UserFerrengi Holdings
Latest ACOR Headlines from TheStreet
- FDA More Problematic Than Obamacare, Says Acorda CEO
04.24.12 | 06:04 am - BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- BIO CEO Conference Live Blog 02.13.12 | 01:02 pm
- 8 Stocks Rising on Huge Volume 01.05.12 | 02:01 pm
- Acorda Rises On Unusually High Volume (ACOR) 11.04.11 | 04:11 pm
- Acorda Stock Hits New 52-Week Low (ACOR) 09.29.11 | 01:09 pm
- SAC Upped Dendreon Exposure Before Blowup 08.15.11 | 05:08 pm
- 5 Biotech Drug-Launch Stocks to Watch 07.18.11 | 09:07 am
- Acorda Stock Gaps Up On Today's Open (ACOR) 05.20.11 | 09:05 am
- European Regulators Approve New Drugs 05.20.11 | 07:05 am
Press Releases for ACOR
- Robbins Umeda LLP Announces An Investigation Of Acorda Therapeutics, Inc. - Business Wire 06.04.12 | 11:06 am
- New Research Presented At 4th Collaborative Meeting Of CMSC And ACTRIMS Expands Understanding Of MS-Related Walking Impairment And Clinical Usage Of AMPYRA® - Business Wire 05.31.12 | 06:05 am
- Acorda Therapeutics Launches First-Ever Online Talk Show Focusing On Walking Problems In Multiple Sclerosis - Business Wire 05.30.12 | 07:05 am
- Acorda Therapeutics Recognized As One Of The Best Places To Work In New York State For Second Consecutive Year - Business Wire 04.30.12 | 07:04 am
- Acorda Therapeutics Presents AMPYRA® Long-Term Safety And Efficacy Data At 64th American Academy Of Neurology Annual Meeting - Business Wire 04.25.12 | 07:04 am
- Acorda Therapeutics Named One Of The 100 Most Trustworthy Companies By Forbes - Business Wire 04.12.12 | 07:04 am
- Acorda Therapeutics To Provide Pipeline Update At Upcoming R&D Day - Business Wire 04.10.12 | 07:04 am
- Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment With Ampyra® (Dalfampridine) Of Walking Problems In Patients With Multiple Sclerosis - Business Wire 04.02.12 | 08:04 am
- Acorda Therapeutics To Present At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 07:02 am
- Acorda Therapeutics To Present At 2012 RBC Capital Markets' Global Healthcare Conference - Business Wire 02.22.12 | 06:02 am
Partner Headlines for ACOR
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 04.17.12 | 09:04 am
- Biogen's Fampyra Launched in Canada - Analyst Blog - Zacks 04.13.12 | 06:04 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks Ripe For A Takeover - Seeking Alpha 10.28.11 | 05:10 pm
- Notable Call Options Activity in Acorda Therapeutics - Benzinga 10.13.11 | 01:10 pm
- Company News for October 6, 2011 - Corporate Summary - Zacks 10.06.11 | 10:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.12.11 | 09:07 am
